FDA Approves Cefepime-Zidebactam Injection - Top-Institutions - MDSpire

FDA Approves Cefepime-Zidebactam Injection

Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.

  • By

  • Kathryn Wighton

  • June 3, 2026

  • 2 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical School

    New Brunswick, NJ

    Key Differentiators

    • Infectious Disease

  • #2

    Second Xiangya Hospital of Central South University
    Second Xiangya Hospital of Central South University

    Changsha, Hunan

    Key Differentiators

    • Infectious Disease

  • #3

    University of Maryland
    University of Maryland

    Baltimore, MD

    Key Differentiators

    • Infectious Disease

Original Source(s)

FDA Approves Cefepime-Zidebactam Injection

  • by Kathryn Wighton

  • June 3, 2026

Related Content

CDC Updates Cyclosporiasis Surveillance

More than 5,100 additional reports require further analysis as federal and state partners investigate several outbreaks and work to identify their sources.

High-Dose Vitamin C Could Pose Risk in Severe Burns

“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”

Caries May Signal Oral Antibiotic Resistance

Study found species-specific differences in biofilm -forming capacity and antimicrobial susceptibility among supragingival bacterial isolates from patients with active dental caries.